OCENLO
Live / Applied — Third extension granted (statement of use) (as of 24 Mar 2026)
What this means for you
Not registered yet, but its 18 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98229386
- Mark type
- Stylized text
- Filed
- 18 Oct 2023
- Published for opposition
- 06 Aug 2024
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, Princeton, NJ, US
Prosecution history
- 25 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Mar 2026 — SOU EXTENSION 3 GRANTED
- 24 Mar 2026 — SOU EXTENSION 3 FILED
- 24 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 25 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Sept 2025 — SOU EXTENSION 2 GRANTED
- 24 Sept 2025 — SOU EXTENSION 2 FILED
- 24 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Apr 2025 — SOU EXTENSION 1 GRANTED
- 01 Apr 2025 — SOU EXTENSION 1 FILED
- 01 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 Aug 2024 — PUBLISHED FOR OPPOSITION